| Literature DB >> 23505320 |
Moshe Vardi1, Nina S Levy, Andrew P Levy.
Abstract
Vitamin E is a naturally occurring fat-soluble antioxidant which has been proposed as a treatment for both primary and secondary protection against cardiovascular (CV) events. Promising data from observational epidemiological studies associating higher vitamin E dietary intake with lower risk of CV events have not been validated in randomized controlled clinical trials assessing the effect of vitamin E on CV outcomes. While the pendulum of medical opinion has swung to suggest that high dose vitamin E supplements have no place in the treatment and prevention of CV disease, new data is emerging that allows identification of a specific target population for this treatment, namely patients with diabetes mellitus and the haptoglobin genotype 2-2. This review details the scientific basis and clinical evidence related to the effect of vitamin E on CV outcomes, and the importance of proper patient selection in gaining therapeutic benefit from this intervention.Entities:
Keywords: cardiovascular outcomes; diabetes mellitus; haptoglobin
Mesh:
Substances:
Year: 2013 PMID: 23505320 PMCID: PMC3735930 DOI: 10.1194/jlr.R026641
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922